U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H30N6OS
Molecular Weight 426.578
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TENELIGLIPTIN

SMILES

CC1=NN(C(=C1)N2CCN(CC2)[C@@H]3CN[C@@H](C3)C(=O)N4CCSC4)C5=CC=CC=C5

InChI

InChIKey=WGRQANOPCQRCME-PMACEKPBSA-N
InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H30N6OS
Molecular Weight 426.578
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.pmda.go.jp/files/000153594.pdf

Teneligliptin is a DPP IV inhibitor which was developed by Mitsubishi Tanabe Pharma and now is used for the treatment of type 2 diabetes mellitus in Asia under the name Tenelia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.889 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TENELIA

Approved Use

Type 2 diabetes mellitus.

Launch Date

1.33548474E12
PubMed

PubMed

TitleDatePubMed
Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
2012 Oct 1
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes.
2013
Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus.
2013 Nov 27
Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
2013 Sep
Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes.
2014 Aug
Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
2014 Dec
Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
2015
Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
2015 Sep
Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study.
2016
Patents

Sample Use Guides

In Vivo Use Guide
The usual adult dosage is 20 mg of teneligliptin administered orally once daily. If efficacy is insufficient, the dose may be increased up to 40 mg once daily while closely monitoring the clinical course.
Route of Administration: Oral
Human umbilical vein endothelial cells were cultured under normal (5 mmol/L) or high glucose level (25 mmol/L) during 21 days, or at high glucose during 14 days followed by 7 days at normal glucose, to reproduce the high-metabolic memory state. At this time, different concentrations of teneligliptin (0.1, 1.0 and 3.0 umol/L) were added to cells. Teneligliptin was shown to protect human umbilical vein endothelial cells from oxidative stress.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:17:10 UTC 2023
Edited
by admin
on Fri Dec 15 17:17:10 UTC 2023
Record UNII
28ZHI4CF9C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TENELIGLIPTIN
INN   WHO-DD  
INN  
Official Name English
MP-513
Code English
teneligliptin [INN]
Common Name English
Teneligliptin [WHO-DD]
Common Name English
TENELIGLIPTIN [MI]
Common Name English
((2S,4S)-4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YL)(1,3-THIAZOLIDIN-3-YL)METHANONE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C98086
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
Code System Code Type Description
DRUG BANK
DB11950
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
INN
8994
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
MERCK INDEX
m11707
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
DRUG CENTRAL
4895
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
CAS
760937-92-6
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
PUBCHEM
11949652
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
SMS_ID
100000138879
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
NCI_THESAURUS
C87623
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
WIKIPEDIA
Teneligliptin
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
FDA UNII
28ZHI4CF9C
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
EPA CompTox
DTXSID30997419
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
EVMPD
SUB79262
Created by admin on Fri Dec 15 17:17:10 UTC 2023 , Edited by admin on Fri Dec 15 17:17:10 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY